Quarterly ResultMay 7, 2026, 07:07 AM
NewAmsterdam Pharma Q1 Loss $(48.44)M; EPS $(0.40)
AI Summary
NewAmsterdam Pharma reported an increased net loss of $(48.44) million for the first quarter of 2026, compared to $(39.53) million in the prior year, with basic and diluted net loss per share worsening to $(0.40). This occurred despite a slight revenue increase to $3.04 million and an improved operating loss of $(58.42) million. The company also noted a change in the valuation method for its Public Warrant liability due to decreased market activity.
Key Highlights
- Net loss for Q1 2026 increased to $(48.44) million from $(39.53) million in Q1 2025.
- Basic and diluted net loss per share worsened to $(0.40) in Q1 2026 from $(0.34) in Q1 2025.
- Revenue slightly increased to $3.04 million in Q1 2026 from $2.98 million in Q1 2025.
- Operating loss improved to $(58.42) million in Q1 2026 from $(68.93) million in Q1 2025.
- Cash and cash equivalents decreased to $457.61 million as of March 31, 2026.
- Net cash used in operating activities decreased to $(30.60) million in Q1 2026.
- Public Warrant liability valuation method changed from Level 1 to Level 2.
- Share-based compensation expense rose to $18.00 million from $15.21 million.